$ADRO(ADRO)$ 8:02 am Aduro Biotech reports that an independent Data Monitoring Committee, recommended that Phase 2b Eclipse trial of LADD and GVAX continue as planned without modification (ADRO) : Co announces that an independent Data Monitoring Committee (:DMC) recommended that the Phase 2b ECLIPSE trial of its novel LADD and GVAX immunotherapies continue as planned without modification based on the successful outcome of a pre-specified futility analysis. The three-arm trial is expected to enroll over 300 patients at 21 clinical trial sites in the US and Canada to evaluate the safety, immune response and efficacy of the combination immunotherapy of CRS-207 in combination with GVAX Pancreas compared to chemotherapy. "We are on track to complete enrollment in the primary cohort of the trial in [3Q15] and look forward to announcing top line results in [1H16]."